Acalabrutinib produced durable responses in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at higher risk of disease progression.
Follow-up results from a phase 1/2 trial of acalabrutinib in CLL / SLL patients further confirm that acalabrutinib is safe & effective.
Patients with acalabrutinib had lower discontinuation rates and a prolonged time to discontinuation compared to pts treated with ibrutinib.
Final data from a phase 1/2 clinical trial with six years of follow-up show that first-line acalabrutinib produces high response rates and rapid, durable responses in patients with CLL
I am grateful to Nathan Vardi for illuminating this incredible story’s corners, and I highly recommend his book.
Our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute. They discussed the results of a new study looking at whether combining the anti-CD20 monoclonal antibody obinutuzumab with the BTK inhibitor acalabrutinib provided any additional survival benefit.
In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical trial to compare acalabrutinib and ibrutinib head-to-head.
In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with none of the more serious abnormal ventricular heart irregularities seen.
The combination of obinutuzumab (Gazyva), acalabrutinib (Calquence), and venetoclax (Venclexta) failed to meet the pre-specified rate of undetectable measurable or minimal residual disease (uMRD) following optimal debulking with bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
